The circadian clock has been implicated in addiction and several forms of depression [1, 2] , indicating interactions between the circadian and the reward systems in the brain [3] [4] [5] . Rewards such as food, sex, and drugs influence this system in part by modulating dopamine neurotransmission in the mesolimbic dopamine reward circuit, including the ventral tegmental area (VTA) and the ventral striatum (NAc). Hence, changes in dopamine levels in these brain areas are proposed to influence mood in humans and mice [6] [7] [8] [9] [10] . To establish a molecular link between the circadian-clock mechanism and dopamine metabolism, we analyzed the murine promoters of genes encoding key enzymes important in dopamine metabolism. We find that transcription of the monoamine oxidase A (Maoa) promoter is regulated by the clock components BMAL1, NPAS2, and PER2. A mutation in the clock gene Per2 in mice leads to reduced expression and activity of MAOA in the mesolimbic dopaminergic system. Furthermore, we observe increased levels of dopamine and altered neuronal activity in the striatum, and these results probably lead to behavioral alterations observed in Per2 mutant mice in despair-based tests. These findings suggest a role of circadian-clock components in dopamine metabolism highlighting a role of the clock in regulating mood-related behaviors.
The Murine Maoa Promoter Is Regulated by Clock Components In Vitro
We analyzed the promoter of Maoa for presence of E-box elements. These elements serve as potential binding sites for heterodimers of CLOCK/BMAL1 or NPAS2/BMAL1, key components of the circadian-clock mechanism [11] . In the promoter of Maoa, we found E-box elements, which are conserved among mouse, rat, and human, suggesting comparable regulation of this gene in these species ( Figure 1A ). To determine whether the Maoa promoter is regulated by clock components, we cloned a 1.1 kb promoter fragment of the murine Maoa (mMaoa) gene containing one canonical and two noncanonical E-boxes into a luciferase reporter vector. Cotransfection with clock components of this reporter construct into the neuroblastoma cell line NG108-15 revealed regulatory effects of clock proteins on the mMaoa promoter ( Figure 1B ) in a concentration-dependent manner (Figure S1A available online). Surprisingly, CLOCK/BMAL1 does not activate the mMaoa promoter in the neuroblastoma cell line ( Figure 1B ) but in COS-7 monkey kidney cells (Table S1 ), suggesting a possible involvement of cell-type-specific cofactors in this process. Cotransfection of Cry1, a clock component of the negative limb of the clock regulatory mechanism [12] , dampened the activation by NPAS2/BMAL1 in neuroblastoma cells. Cotransfection of Per2 resulted in increased activation ( Figure 1B ) as observed previously for the activation of the aminolevulinate synthase 1 promoter [13] . To test whether the conserved classical E-box is of importance in the mMaoa promoter, we deleted it. This resulted in a shortened 0.7 kb promoter that was still activated by NPAS2/BMAL1, however in a strongly reduced manner, indicating functional importance of the most 5 0 E-box in the 1.1 kb construct ( Figures 1A and  1B) . In contrast to mMaoa, neither a 1.2 kb fragment of the murine monoamine oxidase B (mMaob) promoter ( Figure S1B ) nor a 3.3 kb promoter fragment of the tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis (data not shown), displayed comparable effects in our assays. Taken together, our experiments indicate that the mMaoa promoter is prone to specific regulation by clock components in vitro.
The MaoA Gene Is Hardwired Directly to the Circadian Oscillator In order to test circadian functionality of the mMaoa promoter, we transfected the mMaoa-luciferase reporter construct into NG108-15 neuroblastoma cells and followed its expression by using real-time bioluminescence monitoring. After synchronization with dexamethasone [14] , we monitored luciferase activity in the cell population over 4 days ( Figure 1C and Figure S1C ). We observed an w24 hr oscillation of luciferase activity with the same phase as a control reporter construct containing four E-box elements derived from the clock-controlled Dbp gene [15] . Similar results were also obtained upon transfection of the construct into NIH 3T3 fibroblasts cells ( Figure S1C ). This indicates that the mMaoa promoter is capable of oscillating in a circadian fashion.
In a next step, we investigated the regulation of the mMaoa promoter in vivo. We wanted to know whether BMAL1 directly interacts with the mMaoa promoter in brain regions that express this gene. Chromatin immunoprecipitation with antibodies against BMAL1 revealed binding of this protein to the promoter of mMaoa in brain tissue containing the VTA ( Figure 1D ). This binding was also time dependent with *Correspondence: urs.albrecht@unifr.ch significantly more BMAL1 binding at Zeitgeber time (ZT) 6 compared to ZT 18 (p < 0.05, t test) comparable to the timedependent binding of BMAL1 to the promoter of Rev-erba, a circadian-clock component ( Figure 1D ). The lower signal of BMAL1 binding at the mMaoa promoter in vivo probably reflects the fact that fewer cells in the analyzed brain region express mMaoa in a circadian manner as compared to the Rev-erba gene. Binding of BMAL1 is not observed in the promoter region of the mBmal1 gene, a circadian gene that does not regulate itself. BMAL1 binding at the mMaoa promoter was also not observed in the cortex region or the liver of the same animals (data not shown). We conclude that the mMaoa promoter can be regulated by BMAL1 in a time-dependent fashion in brain tissue containing the VTA.
Expression of Maoa Is Reduced in Per2 Mutant Mice

Per2
Brdm1 mutant mice display altered responses to drugs of abuse [2, 16] , implying abnormal signaling in the mesolimbic dopaminergic system of these animals. Therefore, we investigated region-specific and time-dependent expression of mMaoa and mMaob in the mesolimbic system including the striatum and the VTA. We found cycling diurnal expression of mMaoa mRNA in the VTA of wild-type animals (p < 0.01, oneway ANOVA) with a maximum at ZT 6, whereas mMaob expression was not cycling diurnally ( Figure 2A ). No diurnal variation for both mMaoa and mMaob could be detected in Per2
Brdm1 mutant mice having a defective circadian clock (p > 0.05, one-way ANOVA). Significantly lower mRNA levels of Maoa were observed in these animals at ZT 6 (p < 0.05, two-way ANOVA) (Figure 2A ; for micrographs, see Figure S2 ). Diurnal expression for mMaoa was also observed in the ventral striatum (NAc) for both genotypes with reduced expression in Per2
Brdm1 mutants at ZT 6 and ZT 12 (p < 0.05, two-way ANOVA), whereas mMaob expression was not diurnal ( Figure 2B ). However, mMaob expression was lower in Per2
Brdm1 mutants at ZT 18 (p < 0.01, two-way ANOVA). These observations support our finding that the mMaoa promoter can be regulated by clock components and that PER2 probably plays a positive role in this mechanism by increasing the amplitude ( Figures 1B, 2A , and 2B). The expression analyses presented above indicate that mMaoa mRNA is stronger expressed than mMaob in parts of the mesolimbic dopaminergic system, but we do not know whether this translates to the protein level.
MAOA Activity Is Reduced and Dopamine Levels Are Elevated in Per2 Mutant Mice
Alterations in expression of Maoa mRNA in Per2
Brdm1 mutant mice lead us to determine the total activity of MAO (MAOA and MAOB) in the VTA. We find that it follows the mRNA expression pattern of mMaoa with a maximum of MAO activity at ZT 6 and a significantly cycling diurnal variation in wild-type mice (p < 0.05, one-way ANOVA) but no variation (p > 0.05, one-way ANOVA) and reduced activity in Per2
Brdm1 mutants (p < 0.0001, two-way ANOVA) ( Figure 2C ). In the striatum (composed of the caudate Putamen [CPu] and the NAc), to which the VTA projects, MAO activity was diurnal in wild-type mice (p < 0.05, one-way ANOVA). This activity was constant in Per2
Brdm1 mutant animals (p > 0.05, one-way ANOVA). The maximum of activity was delayed to ZT 12 in wild-type animals ( Figure 2D ) compared to the maximal activity in the VTA ( Figure 2C ), and activity was significantly reduced at this 0 upstream region, including the three E-boxes (Maoa 1.1 kb) or a deletion of the canonical E-box (Maoa 0.7 kb) was used for the transcriptional assays. Presence (+) or absence (2) of the reporter and expression plasmids is shown. Each value represents the mean 6 SD of three independent experiments with three replicates for each experiment. (C) Circadian oscillations of luciferase reporter activity in dexamethasone synchronized NG108-15 cells. Detrended, normalized time series, each derived by averaging the bioluminescence profiles of two independent cultures (representative experiment out of three independent experiments), are shown. ''pGL3'' refers to a luciferase reporter (gray, negative control), ''pGL3_4-Ebox'' refers to a pGL3 reporter containing four E-boxes of the Dbp promoter (black, positive control), ''Maoa 1.1kb'' refers to a pGL3 reporter containing a 1.1 kb promoter fragment of the mouse Maoa promoter (light-gray line). (D) Binding of BMAL1 to the mMaoa promoter in mouse brain tissue collected at ZT 6 and ZT 18 as revealed by chromatin immunoprecipitation (ChIP). BMAL1 does not bind to its own promoter (black bars, negative control, p > 0.05, ZT 6 versus ZT 18) but binds in a time-dependent fashion to the mRevErba promoter (gray bars, positive control, p < 0.05, ZT 6 versus ZT 18) and to the mMaoa promoter (white bars, *p < 0.05 and **p < 0.01). Each value represents the mean 6 SEM of three independent experiments with the p values determined by the Student's t test.
time point in Per2
Brdm1 mutant mice ( Figure 2D ) (p < 0.001, twoway ANOVA). The delay of maximal MAO activity in the striatum compared to maximal mMaoa mRNA expression in the ventral striatum (NAc) might be the result of MAO activity in the CPu contributing, besides the NAc, to the total activity in the striatum. However, it appears that the reduced expression levels of mMaoa in Per2
Brdm1 mutants are reflected in the total MAO activity, indicating that in the mouse striatum, dopamine is metabolized predominantly by MAOA under basal conditions. This is consistent with previous findings in Mao-deficient mice [17, 18] . Taken together, our observations indicate that loss of functional PER2 lowers activity of MAO, which appears to be the result of reduced expression of mMaoa. Because dopamine is the most prominent neurotransmitter in the NAc of the striatum, we expected an increase in the dopamine to DOPAC ratio in this region of the brain. We found that this ratio was significantly elevated in the striatum (CPu and NAc) of Per2
Brdm1 mutant mice (p < 0.05, two-way ANOVA) ( Figure 2E ). This is consistent with our finding that MAO activity is reduced. To investigate whether this increase can be observed extracellularly, we performed microdialysis in the ventral striatum (NAc). We find that under basal conditions, dopamine release is significantly increased in Per2 Brdm1 mutant animals compared to wild-type littermates (p < 0.05; two-way ANOVA). Furthermore, we observed in both genotypes diurnal changes in the levels of this neurotransmitter; 
and time (p < 0.01) but no interaction between the two (p > 0.05). Significant differences between the genotypes at ZT 6 (*p < 0.05) and ZT 12 (*p < 0.05) were observed. For mMaob, a significant difference between genotypes was observed at ZT 18 (**p < 0.01). mMaoa was significantly more highly expressed than mMaob in both genotypes (p < 0.001). (C) Enzymatic activity of MAO in the VTA (n = 3 per genotype). Two-way ANOVA revealed a significant effect on genotype (p < 0.0001) and time (p < 0.05) and no interaction between the two factors (p > 0.05). Bonferroni post test shows a significant difference between genotypes at ZT 6 (*p < 0.01) and ZT 0/24 (*p < 0.05). One-way ANOVA shows significant variation of enzyme activity over time in wild-type mice (p < 0.05) and no variation in Per2
Brdm1 animals (p > 0.05). (D) Enzymatic activity of MAO in the striatum (CPu + NAc) (n = 3 per genotype). Two-way ANOVA revealed a significant difference in genotype (p < 0.001) and time (p < 0.05) but no interaction between the two (p > 0.05). Bonferroni post test shows a significant difference between genotypes at ZT 12 (*p < 0.001). One-way ANOVA shows significant variation of enzyme activity over time in wild-type mice (p < 0.05) and no variation in Per2
Brdm1 animals (p > 0.05). (E) Dopamine/DOPAC ratio in the striatum (CPu + NAc). Two-way ANOVA revealed a significant difference in genotype (p < 0.05) and time (p < 0.01) but no interaction between the two (p > 0.05). Bonferroni post test shows a significant difference between genotypes at ZT 0/24 (*p < 0.05). Data for ZT 0 and ZT 24 are double plotted. Values represent the mean 6 SEM. (F) Extracellular levels of dopamine in the ventral striatum (NAc). Per2
Brdm1 animals showed higher basal levels of dopamine release compared to wild-types (p < 0,05; two-way ANOVA for repeated-measures; genotype F 1, 9 = 5.4). A diurnal rhythm was observed in Per2
Brdm1 mice (p < 0.0001; one-way ANOVA; time F 47, 235 = 2.6) as well as in wild-type littermates (p < 0.0001; one-way ANOVA; time F 47, 188 = 2.5). Values represent the mean 6 SEM (n = 5-6 per genotype).
these changes are in opposite phases as compared to MAO activity in the same brain region. We conclude that loss of functional PER2 is likely to lower MAOA activity in the striatum, contributing to increased dopamine levels in Per2
Brdm1 mutant mice in this brain area. In contrast to Maoa-deficient mice that show aggressive behavior and elevated serotonin levels, we did not make these observations in Per2
Brdm1 mutants (data not shown), probably because Maoa expression is not completely eliminated in our mutants. However, studies that associate human MAOA with alcoholism [19, 20] highlight a possible correlation between reduced expression of mMaoa in Per2
Brdm1 mutants and increased ethanol intake in these animals [16] .
Differences in Despair-Based Behavioral Tests between Per2
Brdm1 Mutant and Wild-Type Mice In humans, dopamine levels are related to mood [6] . Because Per2
Brdm1 mutant mice display increased levels of this neurotransmitter in the striatum, we wanted to probe for behavioral alterations by applying despair-based behavioral tests believed to correlate with human mood disorders [21] . We examined wild-type and Per2
Brdm1 mutant mice in the Porsolt forced-swim test (FST) and the tail-suspension test (TST). They measure the duration of immobility occurring after exposure of mice to an inescapable situation. However, they appear to be regulated by different sets of genes and hence may result in different outcomes [22] . These tests could be used because basal locomotor activity in the two genotypes is not different [2, 23] . The FST shows that Per2
Brdm1 mutant mice display significantly less immobility compared to wild-type animals (p < 0.0001, two-way ANOVA, Figure 3A ). This indicates an increase in neurotransmitter levels in Per2
Brdm1 mutants. Because the response to cocaine [2] as well as expression and activity levels of mMaoa was highest at ZT 6 in the VTA, we performed all subsequent behavioral tests at ZT 6. To examine whether the lower immobility in Per2
Brdm1 mutants is due to their elevated dopamine levels ( Figure 2F ), we aimed to diminish the amount of dopamine in these animals. We treated the mice with alpha-methyl-p-tyrosine (AMPT), a potent inhibitor of tyrosine-hydroxylase (TH), the rate-limiting enzyme of catecholamine synthesis, to reduce dopamine levels. We find that AMPT increased immobility in Per2
Brdm1 mutants compared to saline-treated mutants (p < 0.01, t test), and immobility became comparable to saline-treated wild-type mice (nonsignificant difference [ns]; Figure 3B ). We conclude that inhibition of TH leads to a behavioral rescue of Per2
Brdm1 mutants in the FST ( Figure 3B ) indicating an involvement of dopamine (and/or other catecholamines) in this phenotype.
In TST, we find that immobility times are not different between the genotypes ( Figure S3 ). Different outcomes in these despair-based behavioral tests for mice are not unusual [22] . However, because of the comparable behavioral baselines of the two genotypes, we could use the TST to titrate MAO activity with an inhibitor in the two genotypes. Because Per2
Brdm1 mutants show less MAO activity ( Figures 2C and  2D) , we expected these animals to respond to lower doses of tranylcypromine (TCP), a MAO inhibitor. In comparison amitriptyline (AMI), a nonselective monoamine reuptake inhibitor mainly influencing serotonin and noradrenaline levels in the synaptic cleft should be effective at similar doses for both genotypes. We found these predictions to be met by intraperitoneal injections of AMI and TCP ( Figure 3C ). Both genotypes show a similar dose-dependent decrease in immobility for AMI, whereas Per2
Brdm1 mutant mice are more sensitive to TCP. These experiments are in agreement with the observation that mMaoa expression and MAO activity is reduced in Per2
Brdm1 mutants and therefore less inhibitor is necessary to abolish MAO function. Taken together, these findings indicate that Per2
Brdm1 mutants react differently compared to wild-types in tests believed to correlate with human mood disorders.
Electrical Neuronal Activity Is Altered in Per2 Mutant Mice in Response to MAO Inhibitors
To test how electrical activity is affected after treatment with AMI and TCP in wild-type and Per2 mutant mice, we measured neuronal activity in the ventral striatum (NAc) in vivo. Multiunit activity recordings show that wild-type and Per2
Brdm1 mutant animals react similarly to AMI ( Figures 4A, 4B, and 4E) . Interestingly, wild-type mice do not show altered activity traces after injection of 6 mg/kg TCP at ZT 6. In contrast, Per2 mutant mice display a strong response visible in the change of the activity trace after TCP injection at ZT6 (Figures 4C and 4D ). It appears that neuronal activity in Per2 mutant mice is significantly affected compared to that in wild-type animals (p < 0.05, t test, Figure 4E ). This result indicates that Per2 mutants are more sensitive to TCP than wild-type mice. This might be the result of lower amounts of MAOA enzyme due to a reduced expression of the mMaoa gene (Figure 2) . Hence, Brdm1 mutant mice by blocking tyrosine hydroxylase activity with alphamethyl-p-tyrosine (AMPT) at ZT 6. A Student's t test reveals significant differences after AMPT treatment (200 mg/kg) in Per2
Brdm1 mutant mice compared to basal levels and saline treatment (**p < 0.01, n = 9-12) but no significant difference (ns) to saline-treated wild-type animals. (C) Decrease in immobility at ZT 6. Tail-suspension test (TST) performed 30 min after saline injection and the subsequent day 30 min after drug treatment with amitriptyline (AMI) and tranylcypromine (TCP). Concentrations used for AMI were 3, 6, and 9 mg/kg body weight and for TCP 6, 9, and 12 mg/kg body weight (n = 11-18). A Student's t test revealed significant differences between the lowest and the highest dose for the AMI treatment in both genotypes (*p < 0.05). For TCP treatment, only wild-type mice show a significant difference between the lowest and the highest dose (**p < 0.01). This is not the case for Per2 Brdm1 mutant mice, indicating the higher sensitivity of these animals to TCP. Values represent the mean 6 SEM. these mice are potentially useful to screen for drugs targeting MAOA to readjust intracerebral dopamine levels.
The behavioral and neuronal activity measurements for Per2
Brdm1 mutant mice ( Figures 3 and 4 and [2] ) could also be explained by a change in the expression of the dopamine transporter (DAT) and changes in dopamine receptors (DR1 and DR2). This seems to be unlikely because expression of DAT is not significantly altered in Per2
Brdm1 mutants ( Figure S4 ). Furthermore, expression of the excitatory dopamine receptor DR1 is reduced, and expression of the inhibitory dopamine receptor DR2 is elevated ( Figure S4 ). This indicates a compensatory response of the mutant organism to the elevated dopamine concentrations at the level of its receptors.
Conclusions
Taken together, our results indicate a direct influence of circadian-clock components on mMaoa expression and activity in the mesolimbic dopaminergic system. In particular, PER2 appears to act as a positive factor, and its absence leads to reduced Maoa expression and activity resulting in elevated dopamine levels in the ventral striatum (NAc). The behavioral alterations that are observed in Per2 mutant mice with tests modeling human mood disorders are probably due to the elevated dopamine levels. This implies that alterations in the clock, as they occur in shift workers, pilots, and people suffering from jet-lag, may have profound consequences for brain function including mood regulation by the mesolimbic dopaminergic system.
Supplemental Data
Experimental Procedures, four figures, and three tables are available at http://www.current-biology.com/cgi/content/full/18/9/678/DC1/. Brdm1 mutant (white bars) mice (n = 8-11). TCP responses were significantly different between WT and Per2
Brdm1 mutant mice (Student's t test, *p < 0.05). Values represent the mean 6 SEM.
